LIXT — Lixte Biotechnology Holdings Cashflow Statement
0.000.00%
- $3.36m
- $5.82m
Annual cashflow statement for Lixte Biotechnology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -3.26 | -6.73 | -6.31 | -5.09 | -3.59 |
Non-Cash Items | 1.25 | 2.6 | 1.55 | 0.773 | 0.418 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.118 | -0.013 | 0.155 | 0.021 | 0.003 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -2.13 | -4.14 | -4.61 | -4.29 | -3.16 |
Financing Cash Flow Items | — | -0.01 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 4.6 | 3.9 | 5.14 | 3.14 | 0 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.47 | -0.246 | 0.53 | -1.15 | -3.16 |